Abstract:Background: Emerging evidence suggests that female sex may be associated with increased risk of developing antiretroviral toxicities. Although the mechanisms of sex-related antiretroviral pharmacodynamic differences remain poorly understood and may be multifactorial, they appear to be mediated through a common pathway of pharmacokinetic variability between the sexes. Objective: This article reviews sex differences in the pharmacokinetics of the major classes of antiretroviral drugs currently approved for HIV treatment by the US Food and Drug Administration, identifies knowledge gaps, and provides recommendations for future research directions. Methods: To identify pertinent articles for this review, the MEDLINE database was searched from 1990 to June 2006 using the terms sex, gender, antiretroviral therapy, ART, HAART, pharmacokinetics, pharmacodynamics, NRTI, NNRTI, and protease inhibitors. Search results were restricted to English language and human studies. The reference lists of identified articles were also used, as well as abstracts from relevant conferences. In addition, individual antiretroviral drugs were searched by sex/gender or by pharmacokinetics. Results: Current evidence, though limited, does suggest the existence of a sex disparity in antiretroviral pharmacokinetics, and such disparity has been shown to have pharmacodynamic implications for some drugs. Sex-mediated intracellular pharmaco-enhancement was associated with superior antiviral activities for the zidovudine and lamivudine members of the nucleoside reverse transcriptase inhibitor class. There appears to be divergent opinions about whether sex is a significant determinant of either nevirapine or efavirenz plasma concentrations. For certain protease inhibitors (PIs) (eg, saquinavir [SQV] and indinavir [IDV]), clinically significant relationships between sex differences in plasma drug concentrations and clinical outcomes have been observed. There appears to be a trend toward higher drug exposure in women than in men when PIs are boosted with ritonavir (RTV). Nelfinavir, the only PI that is currently administered unboosted with RTV, does not exhibit a sex difference in its plasma concentrations. Unboosted amprenavir exposure was lower in women compared with men. Sex differences in the pharmacokinetics of SQV and IDV were observed only in the setting of RTV boosting. Conclusions: A common weakness in many studies addressing sex-based differences in the pharmacokinetics of antiretroviral drugs is the relatively small number of women participating. Many of these studies were retrospective in design, and some had limited pharmacokinetic parameters for comparison. Antiretroviral treatment trials should be designed with sufficient power (adequate female participation) to detect sex-based differences both in pharmacokinetics and in clinical response. Future studies should explore the molecular basis for sex-based differences in plasma drug concentrations and antiretroviral drug response. The roles of drug transporter proteins and cellular kinases, and the activities of metabolizing enzymes in mediating differential plasma and intracellular antiretroviral concentrations, should be further assessed.

Interaction of Sex and HIV Infection on Renal Impairment: Baseline Evidence from the CHART Cohort.

Prevalence and risk factors for kidney disease in Chinese HIV-Infected patients: A cross-sectional study

Prevalence and Risk Factors for Kidney Disease among Hospitalized PLWH in China

Effects of Aging, Baseline Renal Function and Stage of HIV Infection on Post-Treatment Changes in Renal Function among HIV-infected Patients: a Retrospective Cohort Study

Prevalence and Risk Factors for Renal Insufficiency among Adults Living with HIV in Tanzania: Results from a Cross-Sectional Study in 2020–2021

Higher cardiovascular disease risks in people living with HIV: A systematic review and meta-analysis

Reduced heart rate variability is associated with altered clinical laboratory profile in people living with HIV

Sex and HIV Differences in Preserved Ratio Impaired Spirometry (PRISm) among Ugandans Post-Pneumonia

Incidence of Impaired Kidney Function among People with HIV: a Systematic Review and Meta-Analysis.

Systematic Review and Meta-Analyses of the Interaction Between HIV Infection and COVID-19: Two Years’ Evidence Summary

Longitudinal analysis of immune reconstitution and metabolic changes in women living with HIV: A real-world observational study

Endothelial dysfunction, a predictor of cardiovascular disease in HIV patients on antiretroviral therapy: A systematic review and meta-analysis

Factors influencing left ventricular diastolic dysfunction on echocardiography of people living with HIV in Kunming, China

Cardiac and Renal Comorbidities in Aging People Living With HIV

Age-specific Associations Between HIV Infection and Carotid Artery Intima-Media Thickness in China: a Cross-Sectional Evaluation of Baseline Data from the CHART Cohort.

Antiretroviral pharmacokinetic profile: a review of sex differences

Association between the triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular diseases in people living with human immunodeficiency virus: Evidence from a retrospectively cohort study 2005-2022

High rates of Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis co-infection in people with HIV: a systematic review and meta-analysis

Sex modifies the association between HIV and coronary artery disease among older adults in Uganda

Correction: Interaction of Declined Handgrip Strength and HIV Infection on Neurocognitive Impairment

Inflammation markers and the risk of hypertension in people living with HIV